IPN Share Price

Open 112.60 Change Price %
High 113.70 1 Day -1.70 -1.51
Low 110.70 1 Week -5.65 -4.86
Close 110.70 1 Month -17.45 -13.62
Volume 127640 1 Year 55.33 99.93
52 Week High 129.85
52 Week Low 55.41
IPN Important Levels
Resistance 2 113.48
Resistance 1 112.34
Pivot 111.70
Support 1 109.07
Support 2 107.92
EPA France Most Active Stocks
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
GSZ 17.56 3.97%
GSZ 17.56 3.97%
GSZ 17.56 3.97%
ALALO 0.08 -11.11%
FP 42.72 -1.43%
More..
EPA France Top Gainers Stocks
MLAMY 2.50 8233.33%
MLSRP 3.79 91.41%
MLGES 3.09 31.49%
MLIML 0.64 28.00%
MLSIC 12.88 20.94%
APAM 33.78 15.72%
APAM 33.78 15.72%
MLLOI 3.80 15.15%
DEXB 17.47 13.89%
DEXB 17.47 13.89%
More..
EPA France Top Losers Stocks
MLONE 0.26 -13.33%
ALALO 0.08 -11.11%
ALDIE 1.10 -8.33%
XIL 27.00 -7.94%
DIM 61.80 -7.90%
MLERO 0.35 -7.89%
TVLY 43.52 -7.48%
MLDEX 1.71 -7.07%
FR 59.58 -6.94%
FR 59.58 -6.94%
More..

Ipsen (EPA: IPN)

IPN Technical Analysis 2
As on 21st Jul 2017 IPN Share Price closed @ 110.70 and we RECOMMEND Buy for LONG-TERM with Stoploss of 83.25 & Strong Sell for SHORT-TERM with Stoploss of 115.58 we also expect STOCK to react on Following IMPORTANT LEVELS.
IPN Target for July
1st Target up-side 129.28
2nd Target up-side 135.89
3rd Target up-side 142.5
1st Target down-side 110.42
2nd Target down-side 103.81
3rd Target down-side 97.2
IPN Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Drugs - Generic
Offical website http://www.ipsen.com
IPN Address
IPN
65, quai Georges Gorse
Cedex
Boulogne-Billancourt, 92650
France
Phone: 33 1 58 33 50 00
Fax: 33 1 58 33 50 01
IPN Latest News
Interactive Technical Analysis Chart Ipsen ( IPN EPA France )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Ipsen
IPN Business Profile
Ipsen S.A. operates as a pharmaceutical company worldwide. It offers drugs in the areas of uro-oncology, endocrinology, neurology, gastroenterology, cardiovascular, and cognitive disorders. The company’s products include Decapeptyl, a peptide formulation for injection in the treatment of advanced prostate cancer; Hexvix that is used to enhance detection of bladder cancer; and Somatuline and Somatuline Autogel, which are used in the treatment of acromegaly and neuroendocrine tumours. Ipsen S.A. also offers NutropinAq, a liquid formulation used in the treatment of growth failure in children and growth hormone deficiency in adults; Increlex, a formulation used for the long-term treatment of growth failure in children and adolescents with severe primary insulin-like growth factor 1 deficiency; and Dysport, a botulinum neurotoxin type A complex used to treat spasticity of upper limbs following a stroke, as well as the spasticity of other muscles. In addition, it provides Smecta, a natural clay-based drug used in the treatment of chronic and acute diarrhea; Forlax, a drug based on a linear polyethylene glycol polymer used in the treatment of constipation; and Tanakan that is used in the treatment of age-related cognitive disorders. Further, the company offers Nisis and Nisisco oral formulations containing valsartan used in the treatment of hypertension; and Adenuric for the treatment of gout. Additionally, it is developing products in the areas of neurology, endocrinology, and uro-oncology, including BN82451, Tasquinimod, Somatuline Autogel, Dysport, Dysport Next Generation, and Decapeptyl. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy S.A.